Quantcast

Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014 - abc27 WHTM

Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Thesan Pharmaceuticals, Inc.

SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming an Operating Partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals leading up to their acquisition by Valeant. Before Dow, Dr. Chaudhuri worked at Bertek Pharmaceuticals (a subsidiary of Mylan Laboratories) as Executive Vice President of Scientific Affairs and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy. He also serves on the Board of multiple pharmaceutical companies.

"We are delighted to have Bhaskar join our Board at this time," said Gordon Foulkes, Thesan's CEO. "His superb track record of developing dermatology drugs, his commercialization expertise, and leadership role in the sale of multiple dermatology companies will be a tremendous help to Thesan going forward as we continue to build our Executive leadership team for the future."

"I am truly honored to be included as part of the Thesan team," Dr. Chaudhuri added. "The current portfolio of breakthrough products managed by a world class team gives Thesan the foundation to be a preeminent Dermatology company. I look forward to contributing towards the growth of Thesan and be part of a leading Dermatology organization."

Also at this time, in connection with the recent Series B financing, Dr. Peter Moldt of Novo Ventures will become the new Novo Board member to represent their investment in Thesan. Dr. Moldt has had extensive experience in the biotechnology industry, serving either as CEO, COO or head of R&D in a number of successful companies, including Curalogic A/S, which he founded and then took public in 2006. Dr. Moldt joined Novo Ventures in 2009.

About Thesan Pharmaceuticals, Inc.

Thesan is a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions.
For more information visit: www.thesanpharma.com

Contact:
J. Gordon Foulkes, Ph.D.
Chief Executive Officer
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow